WO2000059448A3 - Association of no-synthase inhibitor(s) and metabolic antioxidant(s) - Google Patents

Association of no-synthase inhibitor(s) and metabolic antioxidant(s) Download PDF

Info

Publication number
WO2000059448A3
WO2000059448A3 PCT/FR2000/000812 FR0000812W WO0059448A3 WO 2000059448 A3 WO2000059448 A3 WO 2000059448A3 FR 0000812 W FR0000812 W FR 0000812W WO 0059448 A3 WO0059448 A3 WO 0059448A3
Authority
WO
WIPO (PCT)
Prior art keywords
several
thiol groups
association
synthase inhibitor
intervening
Prior art date
Application number
PCT/FR2000/000812
Other languages
French (fr)
Other versions
WO2000059448A2 (en
Inventor
Michel Auguet
Jeremiah Harnett
De Lassauniere Pierre Chabrier
Original Assignee
Sod Conseils Rech Applic
Michel Auguet
Jeremiah Harnett
De Lassauniere Pierre Chabrier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic, Michel Auguet, Jeremiah Harnett, De Lassauniere Pierre Chabrier filed Critical Sod Conseils Rech Applic
Priority to CA002365500A priority Critical patent/CA2365500A1/en
Priority to JP2000609013A priority patent/JP2002541077A/en
Priority to EP00915262A priority patent/EP1169005A2/en
Priority to AU36637/00A priority patent/AU3663700A/en
Publication of WO2000059448A2 publication Critical patent/WO2000059448A2/en
Publication of WO2000059448A3 publication Critical patent/WO2000059448A3/en
Priority to NO20014770A priority patent/NO20014770L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention relates to a pharmaceutical composition comprising as an active ingredient one or several substances interfering with the synthesis of nitrogen monoxide by inhibiting NO-synthase and one or several metabolic antioxidants containing thiol groups and intervening in the redox status of the thiol groups, and optionally a pharmaceutically acceptable support. The invention also relates to a product containing one or several NO-synthase inhibitors and one or several metabolic antioxidants intervening in the redox status of the thiol groups, as a combined product in a separated form of said active ingredients.
PCT/FR2000/000812 1999-04-02 2000-03-31 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) WO2000059448A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002365500A CA2365500A1 (en) 1999-04-02 2000-03-31 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
JP2000609013A JP2002541077A (en) 1999-04-02 2000-03-31 Combination of NO synthase inhibitor and metabolic antioxidant
EP00915262A EP1169005A2 (en) 1999-04-02 2000-03-31 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
AU36637/00A AU3663700A (en) 1999-04-02 2000-03-31 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
NO20014770A NO20014770L (en) 1999-04-02 2001-10-01 Association of NO synthase inhibitor (s) and metabolic antioxidants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904134A FR2791571B1 (en) 1999-04-02 1999-04-02 ASSOCIATION OF NO SYNTHASE INHIBITOR (S) AND METABOLIC ANTIOXIDANT (S)
FR99/04134 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000059448A2 WO2000059448A2 (en) 2000-10-12
WO2000059448A3 true WO2000059448A3 (en) 2001-03-08

Family

ID=9543945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/000812 WO2000059448A2 (en) 1999-04-02 2000-03-31 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)

Country Status (9)

Country Link
EP (1) EP1169005A2 (en)
JP (1) JP2002541077A (en)
AR (1) AR023219A1 (en)
AU (1) AU3663700A (en)
CA (1) CA2365500A1 (en)
FR (1) FR2791571B1 (en)
MY (1) MY133230A (en)
NO (1) NO20014770L (en)
WO (1) WO2000059448A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816509B1 (en) * 2000-11-15 2004-02-06 Sod Conseils Rech Applic ASSOCIATION OF CALPAIN INHIBITORS AND OXYGEN REACTIVE TRAPS
US6476073B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating a hangover by enhancing the effectiveness of the human immune system
WO2004073623A2 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
DE602005012089D1 (en) 2005-08-04 2009-02-12 Extarma Ag Liquid composition containing arginine and alpha-lipoic acid to improve sexual function
WO2009111037A2 (en) * 2008-03-04 2009-09-11 Indigene Pharmaceuticals Inc. Compositions and methods for treating nos-associated diseases
JP2011521908A (en) * 2008-05-09 2011-07-28 デューク ユニバーシティ Treatment of diseases based on the finding that thioredoxin regulates nitric oxide release in cells
TWI592156B (en) * 2011-10-04 2017-07-21 艾可達醫療公司 Methods for treating a stroke-related sensorimotor impairment using aminopyridines
US20150025147A1 (en) * 2012-03-02 2015-01-22 Kyowa Hakko Bio Co., Ltd Enhancer for eating activity and/or gastrointestinal activity
JP6509112B2 (en) * 2012-07-03 2019-05-08 プラブダ，ジェイ Methods for the treatment, diagnosis and / or monitoring of the progression of oxo related conditions

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (en) * 1965-06-09 1966-11-28
FR2110465A1 (en) * 1970-10-15 1972-06-02 Richardson Merrell Spa
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
DE4420102A1 (en) * 1994-06-09 1995-12-14 Asta Medica Ag Combination prepns. contg. alpha-liponic acid or its metabolites
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
WO1997016983A1 (en) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5652255A (en) * 1994-03-07 1997-07-29 British Technology Group Limited Potentiation of bioreductive agents
US5801203A (en) * 1991-04-19 1998-09-01 The Children's Medical Center Corporation Nitroglycerine patch
WO1998050004A1 (en) * 1997-05-09 1998-11-12 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
WO1999003365A1 (en) * 1997-07-14 1999-01-28 N.V. Nutricia Nutritional composition containing methionine
WO1999006040A1 (en) * 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (en) * 1965-06-09 1966-11-28
FR2110465A1 (en) * 1970-10-15 1972-06-02 Richardson Merrell Spa
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
US5801203A (en) * 1991-04-19 1998-09-01 The Children's Medical Center Corporation Nitroglycerine patch
US5652255A (en) * 1994-03-07 1997-07-29 British Technology Group Limited Potentiation of bioreductive agents
DE4420102A1 (en) * 1994-06-09 1995-12-14 Asta Medica Ag Combination prepns. contg. alpha-liponic acid or its metabolites
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
WO1997016983A1 (en) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1998050004A1 (en) * 1997-05-09 1998-11-12 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
WO1999003365A1 (en) * 1997-07-14 1999-01-28 N.V. Nutricia Nutritional composition containing methionine
WO1999006040A1 (en) * 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FAUST, ANTJE ET AL: "Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice", INT. J. IMMUNOPHARMACOL. (1994), 16(1), 61-6, XP000874255 *
LOSKE, C. ET AL: "Cytotoxicity of advanced glycation end products is mediated by oxidative stress", J. NEURAL TRANSM. (1998), 105(8-9), 1005-1015, XP000874257 *
RODRIGUEZ-ARIZA A ET AL: "Rapid induction of NF-kappaB binding during liver cell isolation and culture: inhibition by L-NAME indicates a role for nitric oxide synthase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1999 APR 2) 257 (1) 145-8., XP000857974 *
SIES H.: "Strategies of antioxidant defense.", EUROPEAN JOURNAL OF BIOCHEMISTRY, (1993) 215/2 (213-219)., vol. 215, no. 2, 1993, pages 213 - 219, XP000874264 *
ZIEGLER D.: "[Pathogenesis of diabetic neuropathy]. PATHOGENESE DER DIABETISCHEN NEUROPATHIE.", DIABETES UND STOFFWECHSEL, (20 NOV 1998) 7/6 (251-266)., XP000866219 *

Also Published As

Publication number Publication date
FR2791571B1 (en) 2002-10-04
CA2365500A1 (en) 2000-10-12
WO2000059448A2 (en) 2000-10-12
FR2791571A1 (en) 2000-10-06
MY133230A (en) 2007-10-31
AR023219A1 (en) 2002-09-04
EP1169005A2 (en) 2002-01-09
NO20014770D0 (en) 2001-10-01
AU3663700A (en) 2000-10-23
JP2002541077A (en) 2002-12-03
NO20014770L (en) 2001-11-23

Similar Documents

Publication Publication Date Title
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
MY119231A (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0200623A3 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
WO1997015555A3 (en) Imidazole derivatives and the use thereof as nitrogen monoxide synthase inhibitors
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
LV11984A (en) A pharmaceutical composition for the preparation of foamed beverage
AU3287200A (en) Composition comprising isoquercetin and ascorbic acid in a sustained release form
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
EP0841065A3 (en) Use of sericin as antioxidants and tyrosinase inhibitors
WO2003053394A3 (en) Use of apple core extracts in cosmetic or pharmaceutical co mpositions
WO2000059448A3 (en) Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
WO2002070464A3 (en) Hydrazones and their therapeutic use
TWI256292B (en) Reduction inhibitory agent for active oxygen eliminating activity
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA02012889A (en) 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof.
NZ508371A (en) Therapeutic anti-cold agent containing isomalt as an active ingredient
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
WO2002008222A3 (en) HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS
WO2002043666A3 (en) Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
AU2001289714A1 (en) Benzofuran derivatives and their use as antibacterial agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09937306

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609013

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2365500

Country of ref document: CA

Ref country code: CA

Ref document number: 2365500

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000915262

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000915262

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000915262

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)